envafolimab + chemotherapy + recombinant human endostatin

This drug combination consists of envafolimab, a subcutaneously administered PD-L1 immune checkpoint inhibitor; chemotherapy agents (commonly platinum-based doublet chemotherapy); and recombinant human endostatin (Endostar), an anti-angiogenic agent. Envafolimab works by blocking the PD-L1 protein on tumor cells to enhance immune system recognition and destruction of cancer cells. Recombinant human endostatin inhibits angiogenesis by binding to VEGF receptor 2 (VEGF-R2), suppressing vascular endothelial tube formation and normalizing tumor vasculature, which can improve delivery of cytotoxic agents. Chemotherapy acts through cytotoxic mechanisms to kill rapidly dividing cancer cells. The combination is being investigated primarily for advanced non-small cell lung cancer (NSCLC) without driver mutations as a first-line treatment option. This regimen aims to improve efficacy while maintaining tolerability compared with standard chemo-immunotherapy regimens alone.